Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

TRAP1 regulates autophagy in lung cancer cells

TRAP1 regulates autophagy in lung cancer cells INTRODUCTIONTumour Necrosis Factor Receptor‐Associated Protein 1 (TRAP1) is a member of the HSP90 family with predominantly mitochondrial localization, whose cytoprotective role has been widely documented. Several studies suggest that TRAP1 preserves cellular function by protecting mitochondrial function, limiting the effects of oxidative stress either by decreasing reactive oxygen species (ROS)‐mediated oxidation or by attenuating ROS production and through preservation of the mitochondrial membrane potential by limiting mitochondrial permeability transition pore (mPTP) opening through its interaction with HSP90 and cyclophilin D (CypD). Recent studies identify additional cytoprotective roles for TRAP1 in cellular stress responses including the unfolded protein response to ER stress and autophagy. Together, these effects seem to contribute for TRAP1 protective effect against apoptosis. These anti‐apoptotic functions contribute to human oncogenesis. TRAP1 expression is increased in numerous human malignancies. Functionally, inhibition of mitochondrial TRAP1 and related chaperones is cytotoxic to tumour cells, but not normal cells. Anti‐apoptotic functions of TRAP1 confer tumour cells resistance against different chemotherapeutic agents. For these reasons, TRAP1 has been proposed as a potential biomarker and target for anticancer therapies. In this context, mitochondrial‐targeted agents have been developed to selectively inhibit HSP90‐like mitochondrial chaperones inducing cell death and reverting tumour cell multi‐drug‐resistant phenotype.It has http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png European Journal of Clinical Investigation Wiley

TRAP1 regulates autophagy in lung cancer cells

Download PDF
12 pages

Loading next page...
 
/lp/wiley/trap1-regulates-autophagy-in-lung-cancer-cells-ttlwD0jkn7

References (52)

Publisher
Wiley
Copyright
Copyright © 2018 Stichting European Society for Clinical Investigation Journal Foundation. Published by John Wiley & Sons Ltd
ISSN
0014-2972
eISSN
1365-2362
DOI
10.1111/eci.12900
pmid
29383696
Publisher site
See Article on Publisher Site

Abstract

INTRODUCTIONTumour Necrosis Factor Receptor‐Associated Protein 1 (TRAP1) is a member of the HSP90 family with predominantly mitochondrial localization, whose cytoprotective role has been widely documented. Several studies suggest that TRAP1 preserves cellular function by protecting mitochondrial function, limiting the effects of oxidative stress either by decreasing reactive oxygen species (ROS)‐mediated oxidation or by attenuating ROS production and through preservation of the mitochondrial membrane potential by limiting mitochondrial permeability transition pore (mPTP) opening through its interaction with HSP90 and cyclophilin D (CypD). Recent studies identify additional cytoprotective roles for TRAP1 in cellular stress responses including the unfolded protein response to ER stress and autophagy. Together, these effects seem to contribute for TRAP1 protective effect against apoptosis. These anti‐apoptotic functions contribute to human oncogenesis. TRAP1 expression is increased in numerous human malignancies. Functionally, inhibition of mitochondrial TRAP1 and related chaperones is cytotoxic to tumour cells, but not normal cells. Anti‐apoptotic functions of TRAP1 confer tumour cells resistance against different chemotherapeutic agents. For these reasons, TRAP1 has been proposed as a potential biomarker and target for anticancer therapies. In this context, mitochondrial‐targeted agents have been developed to selectively inhibit HSP90‐like mitochondrial chaperones inducing cell death and reverting tumour cell multi‐drug‐resistant phenotype.It has

Journal

European Journal of Clinical Investigation – Wiley

Published: Jan 1, 2018

Keywords: ; ; ; ; ;

There are no references for this article.